Business Combinations (ViroPharrma) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended				0 Months Ended	3 Months Ended		9 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 24, 2014 Viropharma	Sep. 30, 2014 Viropharma	Sep. 30, 2013 Viropharma	Sep. 30, 2014 Viropharma	Sep. 30, 2013 Viropharma	Jan. 24, 2014 Viropharma Minimum	Jan. 24, 2014 Viropharma Maximum	Jan. 24, 2014 Viropharma Currently Marketed Products	Jan. 24, 2014 Viropharma IPR&D
Business Acquisition [Line Items]
Percentage of voting interests acquired							100.00%
Cash consideration paid							$ 3,997.0
Current assets:
Cash and cash equivalents							232.6
Short term investments							57.8
Accounts receivable							52.2
Inventories							203.6
Deferred tax assets							100.2
Purchased call option							346.7
Other current assets							42.9
Total current assets							1,036.0
Non-current assets:
Property, plant and equipment							24.7
Goodwill	2,373.7	621.3	2,373.7	621.3	624.6	644.5	1,528.8
Other intangible assets, net														2,320.0	530.0
Other non-current assets							10.4
Total assets							5,449.9
Current liabilities:
Accounts payable and other current liabilities							109.5
Convertible bond							551.4
Non-current liabilities:
Deferred tax liabilities							695.9
Other non-current liabilities							96.1
Total liabilities							1,452.9
Fair value of identified assets acquired and liabilities assumed							3,997.0
Pro Forma Information
Post acquisition revenues included in consolidated statement of income								154.5		388.9
Post acquisition pre-tax losses included in consolidated statement of income								3.7		82.9
Post acquisition amortization of intangible assets included in consolidated statement of income								28.5		78.6
Post acquisition unwind of inventory fair value adjustment included in consolidated statement of income			90.6	0				18.1		90.6
Post acquisition integration costs included in consolidated statement of income								27.1		87.8
Weighted average amortization period of acquired amortizable intangible assets							22 years
Discount rate used in determining fair value of acquired in process research and development, low rate							9.50%
Discount rate used in determining fair value of acquired in process research and development, high rate							10.00%
Integration and acquisition costs	$ 37.1	$ 18.4	$ 155.8	$ 39.9				$ 27.1	$ 0	$ 122.1	$ 0
Estimated useful life of intangible assets												10 years	23 years